ARTV: Allogeneic NK cell therapy for refractory RA shows strong efficacy and advances to phase III
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing deep B-cell depletion and strong efficacy in early trials. Phase III is underway with robust funding, rapid community-based enrollment, and plans for broader autoimmune indications.Based on Artiva Biotherapeuti…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.